Inhaled Amphotericin B Lipid Complex for Prophylaxis Against COVID-19-associated Invasive Pulmonary Aspergillosis

link.springer.com
inhaled-amphotericin-b-lipid-complex-for-prophylaxis-against-covid-19-associated-invasive-pulmonary-aspergillosis

Recently, Prattes and colleagues published in Intensive Care Medicine a high incidence of coronavirus disease 2019-associated invasive pulmonary aspergillosis (CAPA), according to 2020 ECMM/ISHAM consensus criteria, with a correspondingly high mortality rate.

However, both the guidelines and a Taskforce report published recently only considered host risk factors.

Many work-related aspergillosis outbreaks have been reported due to airborne contamination with Aspergillus spores.

Protective measures against environmental contamination must be taken when there is construction activity on-site in a hospital.

Antifungal prophylaxis is not recommended in mechanical ventilated patients affected by coronavirus disease 2019 (COVID-19).

Read More